Skip to main content
. 2022 Mar 21;24:22. doi: 10.1186/s13058-022-01519-x

Fig. 2.

Fig. 2

OS and BCSS (A, B) in HR-positive breast cancer and (C, D) in TNBC. No significant difference was noted in overall survival between patients with HER2-low breast cancer and those with HER2-IHC 0 breast cancer, but breast cancer-specific survival was significantly better in patients with HER2-low breast cancer than in those with HER2-IHC 0 breast cancer